RT Journal Article
SR Electronic
A1 Nierengarten, Mary Beth
T1 Triple Therapy More Cost-effective than Biologic First in Patients Who Fail MTX
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 51
SP 13
OP 14
DO 10.1177/155989771451010
UL http://mdc.sagepub.com/content/14/51/13.abstract
AB For patients with rheumatoid arthritis (RA) who fail methotrexate (MTX), using a biologic instead of triple therapy first is not a cost-effective use of health care resources due to the large additional costs for very small benefits. This article presents the results of a randomized noninferiority trial that compared the cost-effectiveness of treating patients who fail MTX with a biologic first or adding triple therapy followed by a biologic.